1. Pink Sheet
  2. >>R&D

Sharpless Wonders Why Cancer Success Doesn't Translate To Other Diseases

 
• By Derrick Gingery

Acting US FDA commissioner also said he wants to be nominated to the permanent position.

FDA acting Commissioner Ned Sharpless at Reagan-Udall Foundation for FDA. (1)
Acting FDA Commissioner Norman Sharpless wants the success in cancer drug development disseminated to other disease areas. • Source: File photo

Acting US Food and Drug Administration Commissioner Norman Sharpless wants the oncology community to share the secret of its regulatory success.

During an event on cancer care and policy, Sharpless wondered whether additional tools are necessary to translate the level of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Animal Testing Alternatives: US Pharmacopeia On Its Testing Transition

 
• By Eliza Slawther

In this second of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet which animal testing models have alternative options and highlights where further investment and research is needed to develop appropriate alternatives.

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 
• By Eliza Slawther

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.